BACKGROUND Patients with ischemic heart disease (IHD) are at risk for ventricular tachycardia (VT). Catheter ablation (CA) may reduce this risk.
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Background
Patients with ischemic heart disease (IHD) are at increased risk of incident or recurrent ventricular tachycardia (VT), ventricular fibrillation (VF), and sudden cardiac death. Implantable cardioverter defibrillators (ICDs) are the mainstay of treatment to reduce the incidence of sudden cardiac death by terminating ventricular arrhythmias either by antitachycardia pacing (ATP) or by delivering a shock. [1] [2] [3] However, ICD shocks, whether appropriate or inappropriate, can have negative effects on patients' quality of life [4] [5] [6] [7] and are associated with an increased risk of subsequent mortality. 8, 9 Thus, therapies that can effectively reduce the risk of ICD shocks are of great importance. Catheter ablation (CA) of VT has become established as a means to treat VT and prevent recurrence. 10 Several randomized controlled trials (RCTs) have been conducted comparing CA with other strategies, such as antiarrhythmic drug (AAD) therapy or control, in patients with IHD.
The Heart Rhythm Society (HRS), the European Heart Rhythm Association (EHRA), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS), in collaboration with the American Heart Association (AHA), the American College of Cardiology (ACC), the Japanese Heart Rhythm Society (JHRS), the Brazilian Society of Cardiac Arrhythmias (Sociedade Brasileira de Arritmias Cardíacas [SOBRAC]), and the Pediatric and Congenital Electrophysiology Society (PACES), appointed a writing committee to draft an expert consensus statement to update the 2009 EHRA/ HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias. 10 The Scientific and Clinical Documents Committee of HRS recognized the need for a highquality systematic review and meta-analysis of the published literature by an Evidence Review Committee (ERC) to inform recommendations. Such an effort must be directed toward areas where key clinical questions can be formed and where published data exist. Here, we report the findings of this effort, with the purpose of evaluating the use of CA in preventing VT events in patients with IHD through a systematic review and meta-analysis. For transparency, ERC members' comprehensive disclosure information is available in Appendix 1, as is comprehensive disclosure information for the peer reviewers in Appendix 2.
Methods
This meta-analysis conforms to standard guidelines and is written in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. 11 The PICOT format (P 5 population, I 5 intervention, C 5 comparator, O 5 outcome, T 5 timing, S 5 setting) 12 was used to derive the key clinical question. This question was, "In adults with a history of sustained ventricular tachycardia and ischemic cardiomyopathy, what are the effectiveness and harms of catheter ablation compared to other interventions?"
Data Sources and Search Strategy
We systematically searched MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL), and the Cochrane Database of Systematic Reviews (CDSR) from January 2000 through April 2018 to identify RCTs comparing a strategy of CA vs no ablation in patients with IHD, an ICD, and a history of VT. The following Medical Subject Headings (MeSH) and keywords were used: ventricular tachycardia, ventricular arrhythmia, ventricular fibrillation, catheter ablation, antiarrhythmic agents, and antiarrhythmic drug. All searches were limited to full-text articles published in English. A manual search of references from included studies was also performed.
Study Selection
For the title, abstract, and full-text article review, two investigators independently examined all potentially relevant citations and articles in a parallel manner, using predefined inclusion and exclusion criteria. Studies were included in this systematic review and meta-analysis if they 1) were RCTs; 2) enrolled adults (.18 years of age); 3) enrolled patients with IHD implanted with an ICD and a history of spontaneous VT or syncope with inducible VT; 4) had at least one CA treatment group; and 5) had outcomes of interest data suitable for pooling. Studies were excluded if they were case reports, reviews, editorials, or non-English language publications. The outcomes of interest included appropriate ICD therapies (ICD shock or ATP), appropriate ICD shocks, VT storm (defined as 3 shocks within 24 hours), recurrent VT/VF, cardiac hospitalizations, and all-cause mortality.
Data Extraction
For each study, two investigators used a standardized data abstraction tool to extract all the relevant and specific information. Disagreements were resolved by consensus. Information collected from each study included author, year of publication, interventions, sample size, key inclusion criteria, months of follow-up, class I or III AADs, other cardiovascular drugs, time to last myocardial infarction (MI), prior revascularization, and pertinent patient characteristics. Study authors were contacted for clarification of information not covered in the publication. All included studies are multicenter prospective RCTs. The risk of bias for each study was independently assessed by two investigators using the Cochrane Risk of Bias Tool. 13 This tool includes 7 items covering the following domains: selection bias due to inadequate generation of a randomized sequence, or inadequate concealment of allocations prior to assignment; performance bias due to knowledge of the allocated interventions by participants and personnel during the study; detection bias due to knowledge of the allocated interventions by outcome assessors; attrition bias due to amount, nature, or handling of incomplete outcome data; reporting bias due to selective outcome reporting; and other bias due to problems not previously covered. 13 
Statistical Analysis
All outcome data were pooled using an inverse variance random-effects model producing odds ratios (ORs) and accompanying 95% confidence intervals (CIs) for each endpoint, with between-study heterogeneity (t 2 ) calculated using the Paule-Mandel estimator. The I 2 statistic was calculated to estimate the percentage of variability in the treatment estimate attributable to statistical heterogeneity between studies, with a value .50% considered substantial. 14 Small study effects, including publication bias, were not examined, given fewer than 10 eligible studies were identified. All analyses were performed using the 'meta' package in R (version 3.4.3; the R Project for Statistical Computing).
In order to better quantify the effects of CA on our outcomes of interest, we conducted a random-effects metaregression via iterative maximum likelihood. 15 An analysis evaluating the impact of baseline amiodarone therapy on each of the outcomes of interest was performed. The percentage of patients administered baseline amiodarone was used to conduct meta-regression to examine whether baseline amiodarone therapy altered the effectiveness of CA.
Results
The inclusion and exclusion of citations and articles identified through our systematic literature search is illustrated in Figure 1 . A total of 5 studies evaluating the use of CA in patients with IHD and an ICD published between 2007 and 2017 were included in the analysis (Table 1) . [16] [17] [18] [19] [20] All included studies were multicenter RCTs. Individual study sample sizes ranged from 27 patients to 259 patients. The mean patient age ranged from 64 years to 68 years, and the duration of follow-up was 6-27.9 months. The time to last MI ranged from ,1 year to 15.7 years. The use of AADs varied between studies. The Substrate Mapping and Ablation in Sinus Rhythm to Halt Ventricular Tachycardia (SMASH-VT) study excluded patients treated with class I or III antiarrhythmics 20 ; 3 studies included between 32% and 37% of patients treated with amiodarone and sotalol 16, 18, 19 ; and the Ventricular Tachycardia Ablation versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease (VANISH) trial required patients to have received background amiodarone or another class I or class III AAD within the previous 6 months. 17 ICD programming was standardized in each study; however, recommendations varied between studies. Three studies reported the incidence of ICD therapies, 16, 19, 20 4 studies reported ICD shocks and VT storm, 15, 16, 18, 19 all studies reported all-cause mortality, [16] [17] [18] [19] [20] 4 studies reported hospitalizations for cardiac cause, [15] [16] [17] [18] and 3 studies reported recurrent VT/VF. 16, 18, 19 Trial investigators provided additional outcome results: appropriate ATP or appropriate shocks in VANISH; and appropriate ATP or appropriate shocks, VT storm, and cardiac hospitalizations in Catheter Ablation for Ventricular Tachycardia in Patients with an Implantable Cardioverter Defibrillator (CALYPSO). The majority of studies were at low risk for selection bias, attrition bias, and reporting bias. All studies were at high risk of performance bias due to a lack of blinding of participants and personnel, given the nature of patients being randomized to receiving a procedure or no procedure. Two studies were determined to be at high risk of other biases due to their study design comparing patients who received an ablation with those who received changes in AAD therapy. 17, 18 Additionally, 2 studies were determined to possess a high risk of other biases due to substantial crossover between randomized groups throughout the study (Figure 2 ). 18, 19 Upon meta-analysis, patients who were randomized to CA had decreased odds of appropriate ICD therapies (OR 0.49; 95% CI 0.28-0.87), appropriate ICD shocks (OR 0.52; 95% CI 0.28-0.96), VT storm (OR 0.64; 95% CI 0.43-0.95), and cardiac hospitalizations (OR 0.67; 95% CI 0.46-0.97) vs those who did not undergo CA. There was no evidence of a significant difference in the odds of recurrent VT/VF (OR 0.87; 95% CI 0.41-1.85) or all-cause mortality (OR 0.89; 95% CI 0.60-1.34) between the ablation and no ablation groups (Figures 3 and 4 ).
Post Hoc Sensitivity Analysis and Meta-Regression
The VANISH and CALYPSO trials differed from the other studies included in this meta-analysis in that they compared CA with AAD therapy. Patients in the VANISH trial were randomly assigned to receive either CA (ablation group) with continuation of baseline AADs or escalated AAD therapy (escalated-therapy group). 17 The CALYPSO trial was a comparison of AADs with CA. 18 Due to the differences in trial design, we ran a sensitivity analysis with the removal of these two trials. Upon analysis, the removal of the VANISH and CALYPSO trials decreased the betweenstudy heterogeneity (I 2 5 0% vs 65%) and showed a greater effect of ablation on appropriate ICD shocks (OR 0.38; 95% CI 0.22-0.64). The removal of these two studies resulted in lower odds of VT storm (OR 0.55; 95% CI 0.30-1.01), cardiac hospitalizations (OR 0.58; 95% CI 0.29-1.15), recurrent VT/VF (OR 0.71; 95% CI 0.34-1.50), and all-cause mortality (OR 0.77; 95% CI 0.41-1.46); however, statistical significance was lost for some outcomes, likely due to type 2 error ( Figure 5) . A random-effects meta-regression showed no significant association between baseline amiodarone therapy and appropriate ICD therapies (P 5 .27), VT storm (P 5 .35), cardiac hospitalizations (P 5 .65), or all-cause mortality (P 5 .43). There was, however, a significant association between baseline amiodarone therapy and appropriate ICD shocks (P ,.01). A negative association was seen: as the percentage of patients on concomitant AAD therapy increased, the effectiveness of CA in preventing appropriate ICD shocks decreased ( Figure 6 ).
Adverse Events
Adverse events were variably defined, and some protocols mandated ICD implantation at or soon after randomization, making attribution of adverse events to the ablation procedure or the ICD implantation procedure difficult. However, adverse events related to the ablation procedure occurred in 30 of 315 (9.5%) patients in the ablation arms of the included trials. Adverse events in the control arms were not reported uniformly due to variations in control strategies. In the two trials that directly compared ablation versus AAD therapy, adverse events were more common in the AAD arm than in the ablation arm. 17, 18 
Discussion
In this systematic review of the literature and a meta-analysis of 5 RCTs, we found that CA reduced the likelihood of appropriate ICD therapies, appropriate ICD shocks, VT storm, and cardiac hospitalization vs controls. In a sensitivity analysis, excluding the 2 studies that specifically randomized patients to CA versus AAD, the magnitude of such reductions was increased, although CIs also widened. This result might suggest an effect of AAD in reducing the risk of VT recurrence and ICD therapies, as found in earlier pharmacotherapy trials. 21, 22 Although at first it might appear contradictory that ablation reduced the risk of several VT-related endpoints, but not recurrent VT/VF, this contradiction is likely explained by the different endpoints reported by the trials, meaning some trials did not contribute data to each endpoint in our analysis. For example, only 3 trials, including fewer than half of the total of 635 patients, contributed to the recurrent VT/VF endpoint. In contrast, 4 of 5 trials, including .95% of the total number of patients, contributed to the appropriate ICD shocks and VT storm endpoints; and all trials contributed to the all-cause mortality endpoint, leading to a higher degree of confidence for these findings. Overlap of events was possible; for example, slow VT underdetection of an ICD could count toward recurrent VT/VF but not toward appropriate ICD therapies.
The finding that baseline amiodarone therapy was associated with appropriate ICD shocks could indicate that patients receiving amiodarone had more advanced heart disease, as reported in a subgroup analysis of VANISH, 23 and therefore were at higher risk of receiving ICD shocks. It is also possible that amiodarone was stopped after an acutely successful ablation procedure in some patients, with subsequent recurrence of VT that had been suppressed by amiodarone therapy. However, these interpretations are hypotheses that require confirmation. Of note, only VANISH included a 30-day "blanking" period to allow for full loading of amiodarone 17 ; in the other trials, the duration of amiodarone therapy prior to an endpoint was not reported.
Our results are largely consistent with several other investigations in this field. Three previous meta-analyses did not include the most recently published trials, [24] [25] [26] or included studies available only in abstract form. 24 One systematic review and meta-analysis has focused on prophylactic CA only (excluding trials in which patients were randomized to AAD). 27 However, one of these trials enrolled patients who had received their first ICD shock from a primary prevention ICD after a protocol amendment, 20 whereas the other two enrolled patients after a qualifying VT event, and permitted AAD therapy in both arms. 16, 19 In practice, the choice between starting or changing AAD therapy on the one hand, vs CA on the other, is often the most relevant decision to be made. This question was addressed by two of the included trials. 17, 18 Due to the small size of one of these trials, a separate meta-analysis of these two was not performed. A recent systematic review and meta-analysis of the effect of AAD and CA in patients with an ICD (including substrates other than IHD) is also available. 28 The current study is the only one to use an expert ERC to systematically review the literature on CA in IHD and perform a meta-analysis.
Our study has several limitations. The trials included in this analysis mandated the presence of an ICD, or Figure 6 Random-effects meta-regression evaluating relationship between percentage of concomitant AAD and effectiveness of catheter ablation on reduction of appropriate ICD shocks. The circles represent individual studies, with the size of the circle proportional to the weight of each study. The line represents the best fit line describing the relationship between the percent AAD use in each study (x-axis) and the effect on appropriate ICD shocks (y-axis). As the percentage of AAD users in the studies increased, the beneficial effect of catheter ablation on reducing appropriate ICD shocks decreased. AAD 5 antiarrhythmic drug; ICD 5 implantable cardioverter defibrillator. The ablation procedure was performed in sinus rhythm. The procedure was divided into 3 steps: 1) induction of VT; 2) localization of the myocardial infarct; and 3) targeting the "arrhythmogenic portions" of the infarct for catheter ablation. Programmed stimulation was performed using up to triple extrastimuli and rapid pacing from the right ventricular apex, right ventricular outflow tract, or left ventricle. If only VF or polymorphic VT was inducible, stimulation was repeated after CARTO electroanatomical system* was used in all procedures Yes VT was repeatedly induced until either the same VT morphology was induced, or the patient required multiple shocks to terminate induced rhythms during the procedure NR NR NR e10 implantation of one soon after randomization. Although this requirement likely improved the sensitivity and uniformity of arrhythmia detection, it limits applicability of our results to patients with an ICD and cannot be extrapolated to those without. Different ablation techniques, technologies, and endpoints were used during the timeframe in which these studies were conducted ( Table 2 ). Causes of death were not uniformly reported across all trials. The absolute number of deaths was small, therefore a separate analysis by cause of death (arrhythmic, cardiac, noncardiac) was not performed. We limited our analysis to trials published as a full peer-reviewed article. The authors are aware of at least 3 other prospective trials that were presented in abstract form, and other studies that were closed due to low enrollment and remain unpublished. How inclusion of these trials would have affected our results is unknown.
Conclusion
This systematic review and meta-analysis of 5 RCTs found that patients with IHD who underwent CA for VT experienced decreased odds of appropriate ICD therapies, appropriate ICD shocks, VT storm, and cardiac hospitalization vs those who did not undergo ablation.
first infusing a class I antiarrhythmic drug intravenously (procainamide or ajmaline). Catheter mapping and radiofrequency ablation were performed using either the NaviStar 4-mm tip* standard or the Thermocool 3. x Epicardial approach allowed, no percentages reported.
